The science of epigenetics will get a $95 million boost from a new collaboration between Constellation Pharmaceuticals Inc. and Roche Group. The two companies will launch a sweeping three-year collaboration to seek new treatments for cancer and other diseases based on epigenetics and chromatin biology.